Study to Evaluate Multiple Doses of ERB-041 in Healthy, Female Japanese Subjects

Wyeth is now a wholly owned subsidiary of Pfizer24 enrolled

Overview

The primary objective is evaluate the safety, tolerability, and pharmacokinetics of multiple doses of ERB-041, an investigational drug, in healthy, female Japanese subjects.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Healthy

Interventions

ERB-041DRUG

Eligibility

Sex: FEMALEMin age: 20 YearsMax age: 45 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Healthy as determined by the investigator on the basis of medical history and screening evaluations.

Locations (1)

Unnamed facility

Kan-nondai, Tsukuba-shi, Ibaraki, Japan

Outcomes

Primary Outcomes

safety, pharmacokinetics

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.